Posted by Michael Wonder on 14 Oct 2016
NICE publishes draft guidance on the use of Imbruvica
14 October 2016 - NICE has published draft guidance on the use of Imbruvica (ibrutinib) by patients with Waldenstrom’s macroglobulinaemia.
Ibrutinib is not recommended within its marketing authorisation for treating Waldenstrom’s macroglobulinaemia in adults who have had at least one prior therapy or as first-line treatment when chemo-immunotherapy is unsuitable.
